This bill mandates two key studies related to perimenopause in women, aiming to enhance understanding of hormonal changes and the effectiveness of diagnostic tools for this life stage. The National Institutes of Health (NIH) is directed to evaluate existing evidence concerning the variability of hormone levels in women prior to experiencing perimenopause symptoms, including any baseline patterns in such variability. Concurrently, the Secretary of Health and Human Services (HHS), acting through the U.S. Preventive Services Task Force (USPSTF), must review published evidence on the clinical utility of hormone testing . This review specifically examines whether baseline hormone information meaningfully informs the diagnosis or management of perimenopause. Within 18 months of enactment, both NIH and USPSTF are required to submit a comprehensive report to Congress. This report will summarize their findings, identify existing evidence gaps, and offer recommendations for future research or clinical guidance.